Pharvaris presents data supporting ongoing clinical development of deucrictibant

Pharvaris (PHVS) announced a summary of data that were presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop. “Additional analyses of deucrictibant data demonstrate consistency in the clinical profile shown in both the prophylactic and on-demand treatment settings,” said Berndt Modig, Chief Executive Officer of Pharvaris. “Deucrictibant’s early-onset and durable treatment response in the on-demand setting, the maintenance of attack reduction for over a year and a half in the prophylactic setting, and the potential for deucrictibant to be used together in both the prophylactic and on-demand settings, if needed, provide additional evidence of deucrictibant’s potential in the treatment of bradykinin-mediated angioedema. Pharvaris continues to diligently execute on the deucrictibant clinical program and is planning for two pivotal data readouts in the next 18 months.”